Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Says Cipla Generic Negates Critics Of Anti-Compulsory License Suit

This article was originally published in PharmAsia News

Executive Summary

U.S.-based Bayer said the argument on its court fight in India to overturn a compulsory-licensing decision allowing Natco Pharma to market a generic of its Nexavar (sorafenib) cancer drug has been obviated by Cipla's launch of another generic.

You may also be interested in...



Japan Tirabrutinib Approval Breaks New BTK Ground In Lymphoma

Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.

QUOTED. 30 March 2020. Stephen Hahn.

President Trump on 27 March signed into law a $2.2tn COVID-19 stimulus package that provides $80m to the US Food and Drug Administration for emergency use authorization of medical products. See what FDA commissioner Stephen Hahn said about it here.

State Agencies Sharpen Supplement Market Oversight During Pandemic, With Industry's Thanks

"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III.  He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.

Topics

UsernamePublicRestriction

Register

SC082309

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel